scholarly journals DIURETIC RESISTANCE IN ADVANCED HEART FAILURE: A Literature Review

2021 ◽  
Vol 2 (1) ◽  
pp. 8-15
Author(s):  
Anita Surya Santoso ◽  
Mohammad Saifur Rohman ◽  
Indra Prasetya ◽  
Budi Satrijo
Keyword(s):  
Heart Failure ◽  
Prognostic Factor ◽  
Literature Review ◽  
Cardiac Dysfunction ◽  
Signs And Symptoms ◽  
Underlying Mechanism ◽  
Advanced Heart Failure ◽  
Diuretic Resistance

Advanced heart failure (HF) is used to characterized patients in HF with severe symptoms, recurrent decompensation and severe cardiac dysfunction. The prevalencekof HFkis approximatelyg1-2% of thecadult population inhdeveloped countries and it will be rising more than 10%pamongapeoplec>70ayears of age, whereas estimated theoprevalence ofcpatients with advanced HF is about 1% until 10%cof thekoverallkHFopopulation. Most ofkthe HF hospitalizationssare due to signs and symptoms of fluidcoverload.Recurrent congestionccould worsen patientssoutcomes.Loopdiureticssare recommended for thectreatmentcofkcongestionqinprHF patient. cHowever,cdiureticvresistanceeispavcommon problem issueiinpacuteqdecompensationtofcadvancedochronicrheartwfailureq(ACHF) patients and established prognostic factor. Some early reports estimated the prevalence of diuretic resistance about 20%-30% in HF population. In this review, we will be discuss how to diagnose the advancedvheartufailurepand the underlying mechanism of diuretic resistancebin HF patients. We also describe pharmacologicalvand non-pharmacologicalstrategies to overcome this issue.

Evaluation of Resting Cardiac Power Output as a Prognostic Factor in Patients with Advanced Heart Failure

2017 ◽  
Vol 120 (6) ◽  
pp. 973-979 ◽  
Author(s):  
Omer Yildiz ◽  
Gamze Aslan ◽  
Zumrut T. Demirozu ◽  
Cemal Deniz Yenigun ◽  
Nuran Yazicioglu
Keyword(s):  
Heart Failure ◽  
Prognostic Factor ◽  
Power Output ◽  
Advanced Heart Failure ◽  
Cardiac Power

Diuretic resistance predicts mortality in patients with advanced heart failure

2002 ◽  
Vol 144 (1) ◽  
pp. 31-38 ◽  
Author(s):  
Gerald W. Neuberg ◽  
Alan B. Miller ◽  
Chris M. O'Connor ◽  
Robert N. Belkin ◽  
Peter E. Carson ◽  
...  
Keyword(s):  
Heart Failure ◽  
Advanced Heart Failure ◽  
Diuretic Resistance

scholarly journals Congestion and Diuretic Resistance in Acute or Worsening Heart Failure

2020 ◽  
Vol 6 ◽  
Author(s):  
Ingibjörg Kristjánsdóttir ◽  
Tonje Thorvaldsen ◽  
Lars H Lund
Keyword(s):  
Heart Failure ◽  
Strong Predictor ◽  
Symptom Relief ◽  
Treatment Success ◽  
Signs And Symptoms ◽  
Monitoring And Evaluation ◽  
Diuretic Resistance ◽  
Diuretic Response ◽  
Evidence Based Therapy ◽  
Therapy Treatment

Hospitalisation for acute heart failure (AHF) is associated with high mortality and high rehospitalisation rates. In the absence of evidence-based therapy, treatment is aimed at stabilisation and symptom relief. The majority of AHF patients have signs and symptoms of fluid overload, and, therefore, decongestion is the number one treatment goal. Diuretics are the cornerstone of therapy in AHF, but the treatment effect is challenged by diuretic resistance and poor diuretic response throughout the spectrum of chronic to worsening to acute to post-worsening HF. Adequate dosing and monitoring and evaluation of diuretic effect are important for treatment success. Residual congestion at discharge is a strong predictor of worse outcomes. Therefore, achieving euvolaemia is crucial despite transient worsening renal function.

scholarly journals Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction

Children ◽  
2021 ◽  
Vol 8 (10) ◽  
pp. 872
Author(s):  
Hari P. Tunuguntla ◽  
Kriti Puri ◽  
Susan W. Denfield
Keyword(s):  
Heart Failure ◽  
Cancer Therapy ◽  
Cardiac Dysfunction ◽  
Late Onset ◽  
Advanced Heart Failure ◽  
Cancer Therapies ◽  
Children With Cancer ◽  
Pericardial Disease ◽  
Symptomatic Heart Failure ◽  
Childhood Malignancies

The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction as a result of exposure to chemotherapy and/or radiation. Anthracyclines remain the most common cause of chemotherapy-induced cardiomyopathy (CCM) with varying clinical presentations including: acute, early onset, and late-onset. Many individuals develop cardiac dysfunction over the long-term, ranging from subclinical cardiac dysfunction to end-stage symptomatic heart failure. The focus of this review is on characterization of symptomatic heart failure in children with cancer therapy-related cardiac dysfunction (CTRCD) primarily due to CCM and utilization of advanced heart failure therapies, including ventricular assist device (VAD) support and heart transplantation, with consideration of unique patient-related factors.

Advanced Heart Failure Therapies for Cancer Therapeutics–Related Cardiac Dysfunction

2017 ◽  
Vol 13 (2) ◽  
pp. 327-336 ◽  
Author(s):  
Christopher M. Bianco ◽  
Sadeer G. Al-Kindi ◽  
Guilherme H. Oliveira
Keyword(s):  
Heart Failure ◽  
Cardiac Dysfunction ◽  
Cancer Therapeutics ◽  
Advanced Heart Failure

546 Clinical and neurohormonal correlates of circulating soluble apoptosis markers in decompensated advanced heart failure

2003 ◽  
Vol 2 (1) ◽  
pp. 115-116
Author(s):  
J PARISSIS ◽  
S ADAMOPOULOS ◽  
K VENETSANOU ◽  
D MENTZIKOF ◽  
K KIRANAKOS ◽  
...  
Keyword(s):  
Heart Failure ◽  
Advanced Heart Failure ◽  
Apoptosis Markers
Sign in / Sign up

Export Citation Format

Share Document